The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Open accessAbstract
BACKGROUND: We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy. METHODS: In a randomized, double-blind, phase 3 trial, we compared olanzapine with placebo, in combination with dexamethasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous chemotherapy who were receiving cisplatin (≥70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin. The doses of the three concomitant drugs administered before and after chemotherapy were similar in the two groups. The two groups received either 10 mg of olanzapine orally or matching placebo daily on days 1 through 4. Nausea prevention was the primary end point; a complete response (no emesis and no use of rescue medication) was a secondary end point. RESULTS: In the analysis, we included 380 patients who could be evaluated (192 assigned to olanzapine, and 188 to placebo). The proportion of patients with no chemotherapy-induced nausea was significantly greater with olanzapine than with placebo in the first 24 hours after chemotherapy (74% vs. 45%, P=0.002), the period from 25 to 120 hours after chemotherapy (42% vs. 25%, P=0.002), and the overall 120-hour period (37% vs. 22%, P=0.002). The complete-response rate was also significantly increased with olanzapine during the three periods: 86% versus 65% (P<0.001), 67% versus 52% (P=0.007), and 64% versus 41% (P<0.001), respectively. Although there were no grade 5 toxic effects, some patients receiving olanzapine had increased sedation (severe in 5%) on day 2. CONCLUSIONS: Olanzapine, as compared with placebo, significantly improved nausea prevention, as well as the complete-response rate, among previously untreated patients who were receiving highly emetogenic chemotherapy. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02116530.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With olanzapine being associated with undesired sedation in some situations, 15 it is interesting to note that there was decreased sedation and improved fatigue in the olanzapine arm.”
From Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial (2020) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Group Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,339
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M. C., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,058
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 677
Antipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 594
Bloechl‐Daum, B., Deuson, R. R., Mavros, P., Hansen, M., & Herrstedt, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6382 · Cited by 496
Navari, R. M., Gray, S. E., & Kerr, A. C. (2011) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2011.05.002 · Cited by 316
Self-citationAn Open Trial of Olanzapine for the Treatment of Delirium in Hospitalized Cancer Patients
BREITBART, W. S., Tremblay, A., & Gibson, C. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.3.175 · Cited by 288
Modified intention to treat reporting in randomised controlled trials: systematic review
Abraha, I., & Montedori, A. (2010) · BMJ · doi:10.1136/bmj.c2697 · Cited by 259
Fulton, B., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199753020-00007 · Cited by 251
Research works printed but not linked: 3
- Navari RM, 2015, Drug Des Devel Ther, 9, 155
- Allison DB, 2001, J Clin Psychiatry, 62, 22
- Hale AS, 1997, Br J Hosp Med, 58, 442
Cited by
Sorted by citations
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K. E. B., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 643
Burstein, H. J., Krilov, L., Aragon‐Ching, J. B., Baxter, N. N., Chiorean, E. G., Chow, W. A., Groot, J. F. D., Devine, S. M., DuBois, S. G., El‐Deiry, W. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5292 · Cited by 603
NCCN Guidelines Insights: Antiemesis, Version 2.2017
Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S. Y., Bergsbaken, J., Bierman, P. J., Brandt, D. S., Dolan, D. E., Ellis, G., Kim, E. J., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0117 · Cited by 254
Self-citationDranitsaris, G., Molassiotis, A., Clemons, M. J., Roeland, E. J., Schwartzberg, L. S., Dielenseger, P., Jordan, K., Young, A., & Aapro, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx100 · Cited by 238
Hashimoto, H., Abé, M., Tokuyama, O., Mizutani, H., Uchitomi, Y., Yamaguchi, T., Hoshina, Y., Sakata, Y., Takahashi, T. Y., Nakashima, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30678-3 · Cited by 229
Metadata
- Authors
- Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-07-14
- Volume
- 375
- Issue
- 2
- Pages
- 134-142
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5344450
- OpenAlex
- W2460792208
- Semantic Scholar
- e1dd1b394f61bd93ef976725f95376ef359b5a7d
- Cited by
- 452
- References
- 57
- Citations by year
- 2026: 28 · 2025: 46 · 2024: 56 · 2023: 43 · 2022: 36 · 2021: 39 · 2020: 54 · 2019: 34 · 2018: 54 · 2017: 52 · 2016: 9
- FWCI
- 55.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (UG1CA189823, UG1CA189825, UG1CA189830, U10CA180790, U10CA180867, CA035269, U10CA035269, P50CA108961, UG1CA189956, UG1CA189819, P30CA012197, P30CA015083)
- National Center for Research Resources (M01RR000585, M01RR007122, M01RR000034)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Keywords
- olanzapine, chemotherapy-induced nausea and vomiting, antiemetic prophylaxis, highly emetogenic chemotherapy, cisplatin, dexamethasone, aprepitant, fosaprepitant, 5-HT3 receptor antagonists, sedation, complete response
- MeSH terms
- Olanzapine, Aprepitant, Adult, Aged, Aged, 80 and over, Antiemetics, Antineoplastic Agents, Benzodiazepines, Dexamethasone, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Morpholines, Nausea, Vomiting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
